Celon Labs launches emulsion-based drug to treat Black Fungus

Hyderabad firm develops an alternative emulsion-based formulation in three weeks, to overcome the short supply of Liposomal Amphotericin B

Hyderabad: Hyderabad-based specialty biopharmaceutical manufacturer, Celon Laboratories, launched an alternative drug-Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus. The drug is set to be made available in the market from next Monday onwards.

Amphotericin B is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among Covid-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany— lipoids.

---

To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation. The drug whose pricing is not yet revealed, uses Amphotericin B as a bulk drug besides soybean oil, egg lecithin and glycerin.

Exhaustively developed by Celon’s in-house R & D team in a record three weeks, the emulsion-based formulation will provide hospitals and Covid-19 treatment centres with increased resources to treat the Black Fungus.

Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.

Celon Labs’ MD M Nagesh Kumar, said, “The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying to the domestic market soon.”

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

---